on CROSSJECT (EPA:ALCJ)
CROSSJECT launches a capital increase of nearly 5 million euros
On June 4, 2025, pharmaceutical company CROSSJECT announced the launch of a capital increase with preferential subscription rights. The initial amount is planned at €4,978,678.60, which could reach €5,725,479.20 if the extension clause is exercised.
This transaction will fund the final development phases of ZEPIZURE®, an emergency treatment for epileptic seizures, and support research for other projects such as ZENEO Adrenaline and ZENEO Hydrocortisone. The subscription period is scheduled to run from June 12 to 20, 2025, with a subscription price set at €1.40 per share, representing a discount of 22.6% compared to the last closing price on June 3, 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news